#USA #Robbins Geller #San Diego #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals Investors Have Opportunity for Class Action

In a significant development for investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), the prominent law firm Robbins Geller Rudman & Dowd LLP has issued a notice encouraging affected investors to consider participating as lead plaintiffs in a class action lawsuit. The announcement indicates that those who purchased or acquired shares of Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, may have suffered substantial losses and have until August 11, 2025, to seek this lead plaintiff designation.

Background of the Case

The lawsuit, titled Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), accuses Rocket Pharmaceuticals and one of its top executives of breaching the Securities Exchange Act of 1934. The allegations stem from a pivotal clinical trial involving RP-A501, a gene therapy aimed at treating Danon disease, where various adverse safety issues have been reported. Examples include the death of participants enrolled in the study, which the company allegedly failed to disclose to its investors.

The lawsuit asserts that Rocket Pharmaceuticals misinformed its investors about the safety and efficacy of RP-A501 while simultaneously concealing critical details regarding the trial's protocol. Notably, the trial’s protocol was amended without transparency, introducing an immunomodulatory agent that contributed to serious health risks among participants.

Recent Developments

On May 27, 2025, Rocket Pharmaceuticals revealed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the Phase 2 study of RP-A501 after a serious adverse event, leading to one participant's death. This disclosure resulted in a significant decline in Rocket's stock price, prompting investor concern and outrage. Many investors who had faith in the potential of RP-A501 to find treatment for Danon disease now find themselves facing substantial financial losses.

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 empowers investors, who purchased Rocket Pharmaceuticals' stock during the class period, to seek the appointment as lead plaintiff. The role of a lead plaintiff is to represent other class members throughout the litigation, making decisions that affect the direction of the lawsuit. This appointment is typically awarded to the investor with the most at stake who can adequately represent the class.

Potential lead plaintiffs can choose any law firm to handle the litigation process, enabling them to navigate the complex legal landscape surrounding these types of cases. It's essential to note that an individual’s likelihood of recovering funds in a successful settlement is not contingent on holding the lead plaintiff status, allowing many to participate in the lawsuit without the pressure of this designation.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is recognized as one of the leading law firms specializing in securities fraud and related litigation. They have achieved remarkable success in obtaining monetary compensation for investors, being ranked #1 by ISS Securities Class Action Services for four out of the last five years. Noteworthy accomplishments include recovering over $2.5 billion for investors in 2024 alone across various securities-related class actions. The firm’s strong track record, including the largest ever recovery of $7.2 billion from the Enron scandal, underscores its capability in handling complex cases involving securities fraud.

For more information on how to proceed, investors can visit the designated page on their website, or contact attorneys J.C. Sanchez or Jennifer N. Caringal directly at 800-449-4900 or via email at [email protected]. This class action lawsuit not only presents a chance for financial redress for affected investors but also shines a light on the critical responsibilities that biotechnology companies have towards their shareholders.

In summary, if you are a Rocket Pharmaceuticals investor who has faced financial losses during the specified class period, taking action now could be essential in this ongoing legal battle. Don’t miss out on the opportunity to potentially reclaim your losses through this class action lawsuit, as many investors band together to seek justice and accountability from the company and its executives.